Cronos Group (NASDAQ: CRON) hasn't been a really serious contender in the marijuana market. On the revenue front, it doesn't compare to the bigger vertically integrated cannabis businesses, and operationally, it struggles to turn a profit and continually burns through cash. While Cronos obviously hopes the U.S. will become a much bigger piece of its business down the road, in the meantime, this choice only serves to emphasize that its U.S. sales -- mainly of hemp-derived cannabidiol products -- aren't doing all that well. Read More...
TipRanks
Morgan Stanley Pounds the Table on Amazon Stock
Even after a sustained period of share losses, Amazon (AMZN) stock is still pricey, with one share going for $2,936.35. That, however, is about to come an end. On Wednesday, the tech giant announced it would enact a 20-for-1 stock split, which will go into effect on June 6, should the move be given the go ahead by shareholders in May. If that wasn’t enough to satisfy investors, the company also said it rebought $800 million of shares under its old repurchase authorization and has given the green
Add Comment